临床早期黏液性和浆黏液性卵巢癌淋巴结转移发生率:一项回顾性队列研究
该回顾性研究基于荷兰病理登记库(PALGA)2002–2012年数据,分析915例黏液性卵巢癌(MOC)患者。426例接受淋巴结取样,其中8例发现淋巴结转移(LNM)。G1期LNM为4/190(2.1%),G2期为1/115(0.9%),G3期为3/22(13.6%)。临床早期MOC患者淋巴结取样无无病生存(DFS)获益。结论认为无临床怀疑LNM的早期G1和G2期MOC中LNM罕见,可省略淋巴结取样。
要点
- 临床早期G1和G2期MOC无临床怀疑LNM时,淋巴结转移罕见。
- G1期LNM发生率2.1%(4/190),G2期0.9%(1/115),G3期13.6%(3/22)。
- 临床早期MOC患者淋巴结取样未显示DFS获益。
核心结论
- 无临床怀疑LNM的早期G1和G2期MOC中LNM罕见,因此这些患者可省略淋巴结取样。
研究设计与样本
- 回顾性研究,数据来自荷兰病理登记库(PALGA),纳入2002–2012年荷兰诊断的915例MOC患者。
主要发现
- 915例MOC患者中426例接受淋巴结取样,8例发现LNM。
- G1期LNM为4/190(2.1%),G2期为1/115(0.9%),G3期为3/22(13.6%);99例肿瘤分级未明确。
- 426例中267例接受细胞减灭术,222例接受分期但未行淋巴结取样。
- 临床早期MOC患者淋巴结取样无DFS获益。
临床怎么用
- 作者认为,无临床怀疑LNM的临床早期G1和G2期MOC患者可省略淋巴结取样。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The use of lymph node sampling during staging procedures in clinical early-stage mucinous ovarian carcinoma (MOC) is an ongoing matter of debate. Furthermore, the incidence of lymph node metastases (LNM) in MOC in relation to tumour grade (G) is unknown. We aimed to determine the incidence of LNM in clinical early-stage MOC per tumour grade. DESIGN: Retrospective study with data from the Dutch Pathology Registry (PALGA). SETTING: The Netherlands, 2002-2012. POPULATION OR SAMPLE: Patients with MOC. METHODS: Histology reports on patients with MOC diagnosed in the Netherlands between 2002 and 2012 were obtained from PALGA. Reports were reviewed for diagnosis, tumour grade and presence of LNM. Clinical data, surgery reports and radiology reports of patients with LNM were retrieved from hospital files. MAIN OUTCOME MEASURES: Incidence of LNM, disease-free survival (DFS). RESULTS: Of 915 patients with MOC, 426 underwent lymph node sampling. Cytoreductive surgery was performed in 267 patients. The other 222 patients received staging without lymph node sampling. In eight of 426 patients, LNM were discovered by sampling. In four of 190 (2.1%) patients with G1 MOC, LNM were present, compared with one of 115 (0.9%) patients with G2 MOC and three of 22 (13.6%) patients with G3 MOC. Tumour grade was not specified in 99 patients. Patients with clinical early-stage MOC had no DFS benefit from lymph node sampling. CONCLUSIONS: LNM are rare in early-stage G1 and G2 MOC without clinical suspicion of LNM. Therefore, lymph node sampling can be omitted in these patients. TWEETABLE ABSTRACT: Lymph node sampling can be omitted in clinical early-stage G1 and G2 mucinous ovarian cancer.
引用
- van Baal J, Van de Vijver KK, Coffelt SB, et al. Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study. BJOG. 2016. PMID: 27860146. doi:10.1111/1471-0528.14425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。